Babies born too early (preterm) have a higher risk of dying in the first weeks of life than babies born at full-term. Those who survive often have damage including cerebral palsy, blindness, deafness or physical disabilities. Magnesium sulphate, used as a neuroprotective factor in pre-term birth, can prevent this damage.
The West of England Academic Health Science Network undertook an ‘evidence into practice’ project (PreCePT) in partnership with five member trusts from February 2014 to March 2015
CLAHRC West is carrying out a quantitative evaluation of the PreCePT project. The researchers are looking at the impact on improved uptake of magnesium sulphate and monitoring this uptake in the long-term in the individual trusts. Preliminary findings show considerably higher uptake than the UK average following the PreCePT project.
The study will show whether the PreCePT intervention significantly improved uptake of magnesium sulphate in participating trusts. It will allow future evaluation of the long term impact on neurological disabilities. We also hope to find partners and funding to roll-out the PreCePT intervention outside the West region and evaluate its effectiveness.